Porphyria cutanea tarda: a case report.


Journal

Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382

Informations de publication

Date de publication:
21 Jan 2019
Historique:
received: 16 06 2018
accepted: 18 12 2018
entrez: 22 1 2019
pubmed: 22 1 2019
medline: 2 5 2019
Statut: epublish

Résumé

The porphyrias are a rare group of metabolic disorders that can either be inherited or acquired. Along the heme biosynthetic pathway, porphyrias can manifest with neurovisceral and/or cutaneous symptoms, depending on the defective enzyme. Porphyria cutanea tarda, the most common type of porphyria worldwide, is caused by a deficiency of uroporphyrinogen decarboxylase, a crucial enzyme in heme biosynthesis, which results in an accumulation of photosensitive byproducts, such as uroporphyrinogen, which leads to the fragility and blistering of sun-exposed skin. Porphyria cutanea tarda is a condition that affects the liver and skin by reduction and inhibition of uroporphyrinogen decarboxylase enzyme in erythrocytes. Areas of skin that are exposed to the sun can generate blisters, hyperpigmentation, and, sometimes, lesions that heal leaving a scar or keratosis. Liver damage might present in a wide range of ways from liver function test abnormalities to hepatocellular carcinoma. The toxic effect of iron plays a role in liver damage pathogenesis. A 59-year-old Turkish man presented with hyperpigmented skin lesions, fatigue, and elevated ferritin level and liver function tests. He was diagnosed as having porphyria cutanea tarda after a clinical investigation and treated with phlebotomy. Porphyria cutanea tarda is a rare condition of the liver but it must be remembered in a differential diagnosis of liver disease with typical skin involvement to decrease morbidity and health costs with early treatment.

Sections du résumé

BACKGROUND BACKGROUND
The porphyrias are a rare group of metabolic disorders that can either be inherited or acquired. Along the heme biosynthetic pathway, porphyrias can manifest with neurovisceral and/or cutaneous symptoms, depending on the defective enzyme. Porphyria cutanea tarda, the most common type of porphyria worldwide, is caused by a deficiency of uroporphyrinogen decarboxylase, a crucial enzyme in heme biosynthesis, which results in an accumulation of photosensitive byproducts, such as uroporphyrinogen, which leads to the fragility and blistering of sun-exposed skin. Porphyria cutanea tarda is a condition that affects the liver and skin by reduction and inhibition of uroporphyrinogen decarboxylase enzyme in erythrocytes. Areas of skin that are exposed to the sun can generate blisters, hyperpigmentation, and, sometimes, lesions that heal leaving a scar or keratosis. Liver damage might present in a wide range of ways from liver function test abnormalities to hepatocellular carcinoma. The toxic effect of iron plays a role in liver damage pathogenesis.
CASE PRESENTATION METHODS
A 59-year-old Turkish man presented with hyperpigmented skin lesions, fatigue, and elevated ferritin level and liver function tests. He was diagnosed as having porphyria cutanea tarda after a clinical investigation and treated with phlebotomy.
CONCLUSION CONCLUSIONS
Porphyria cutanea tarda is a rare condition of the liver but it must be remembered in a differential diagnosis of liver disease with typical skin involvement to decrease morbidity and health costs with early treatment.

Identifiants

pubmed: 30661508
doi: 10.1186/s13256-018-1956-9
pii: 10.1186/s13256-018-1956-9
pmc: PMC6340172
doi:

Substances chimiques

Uroporphyrinogen Decarboxylase EC 4.1.1.37

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Références

Australas J Dermatol. 2000 Nov;41(4):197-206; quiz 207-8
pubmed: 11105361
Dig Dis Sci. 2002 Feb;47(2):419-26
pubmed: 11855561
JAMA. 1963 Jan 12;183:88-91
pubmed: 14018209
N Engl J Med. 1960 Aug 25;263:397-8
pubmed: 14442995
Cutis. 2004 Mar;73(3):188-90
pubmed: 15074347
Br J Haematol. 2006 Nov;135(3):281-92
pubmed: 16956347
Cutis. 2006 Dec;78(6):397-400
pubmed: 17243426
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5079-84
pubmed: 17360334
Cutis. 2007 Nov;80(5):415-8
pubmed: 18189029
Photochem Photobiol. 2008 Mar-Apr;84(2):450-62
pubmed: 18248499
J Intern Med. 2011 Mar;269(3):278-88
pubmed: 20412370
Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):735-45
pubmed: 20955974
Mol Med. 2011 Mar-Apr;17(3-4):241-7
pubmed: 20957336
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1402-9
pubmed: 22985607
Folia Biol (Praha). 2015;61(6):219-26
pubmed: 26789143
Australas J Dermatol. 1988 Apr;29(1):3-8
pubmed: 3250437
J Lab Clin Med. 1986 Jan;107(1):36-42
pubmed: 3941293
Br J Dermatol. 1974 Jan;90(1):95-100
pubmed: 4811840
Acta Derm Venereol. 1981;61(4):346-50
pubmed: 6173993
Rev Med Chil. 1996 Apr;124(4):456-60
pubmed: 9110486
Photodermatol Photoimmunol Photomed. 1997 Jun;13(3):75-7
pubmed: 9372518

Auteurs

Hanife Usta Atmaca (H)

Istanbul Training and Research Hospital, Internal Medicine Department, University of Health Sciences, Istanbul, Turkey. hanifeusta@yahoo.com.

Feray Akbas (F)

Istanbul Training and Research Hospital, Internal Medicine Department, University of Health Sciences, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH